PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 14, 2026Open Forum Infectious Diseases0 citationsOpen Access

P-3. Investigating the Surge of Group C and G Streptococcal Bacteremia in a Rhode Island Community Hospital

View Full Paper
ACA. ChanAOAnais OvalleHZHadeel Zainah

Key Points

  • This research aims to assess the incidence and burden of Group C/G streptococcal bacteremia in a Rhode Island hospital.
  • Conducted a retrospective chart review
  • Included 92 patients with positive blood cultures for Group C/G streptococci or S. dysgalactiae
  • Analyzed demographic and clinical variables, with outcomes noted
  • Statistically significant rise in S. dysgalactiae bacteremia from 2020-2024
  • 72% of cases had skin and soft-tissue infections as the primary source
  • Co-morbidities included hypertension and diabetes mellitus

Abstract

Abstract Background Streptococcus dysgalactiae is a gram positive, beta-hemolytic bacteria of Lancefield’s groups C and G. Once considered non-pathogenic to humans, S. dysgalactiae is now recognized as a cause of diverse infections, from mild pharyngitis to life-threatening soft-tissue necrosis and bacteremia. Increasing incidence of invasive Group C/G streptococcal disease has been reported in western Norway and Finland, yet U.S. surveillance data remain limited. Methods With Institutional Review Board approval, we conducted a retrospective chart review to assess the burden of Group C/G/S. dysgalactiae bacteremia in a 359-bed acute care hospital in Rhode Island, USA. This study included 92 patients admitted between August 2015 and May 2024 with positive blood cultures for Group C or G streptococci or S. dysgalactiae subspecies. We collected and analyzed demographic (age, sex, comorbidities, race), clinical (bacteremia duration, co-infections, antimicrobial resistance), and outcome variables (length of stay, survival at discharge and at 6 moths). Patients were stratified into two cohorts: pre-pandemic (2015-2019) and pandemic/post-pandemic (2020-2024) to assess potential trends related to the COVID 19 era. Results Most common co-morbidities were hypertension, diabetes mellitus, congestive heart failure and chronic kidney disease. Active malignancy at time of admission (7%) and immune suppression with known chemotherapy or immunomodulator (8%) was also noted. The primary bacteremia source was skin and soft-tissue infection in (72%). A statistically significant increase in Group C/G/S. dysgalactiae bacteremia was observed in 2020-2024 with S. dysgalactiae being the most isolated (p=0.0001). However, demographics, clinical variables, and study outcomes were similar between the two groups. Conclusion S. dysgalactiae is a quickly emerging bacteremia causing pathogen. The significant post 2020 increase suggests a potential association with pandemic related factors. Further investigation is needed on how the COVID-19 pandemic may have created opportune environment for these invasive streptococcal infections. Disclosures All Authors: No reported disclosures

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chan et al. (2026) studied this question.

synapsesocial.com/papers/6966f33213bf7a6f02c010f1https://doi.org/10.1093/ofid/ofaf695.234
Ask AI
Helpful
Bookmark
Share
View Full Paper